Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fees Should Be A Last Resort For NICE Funding, Says UK Medtechs

Executive Summary

UK industry has given its rationale for opposing health technology assessment fees from NICE, but suggests that it might be prepared to discuss the general theme of NICE funding if the conditions were right.

You may also be interested in...



UK Looks To Model New Medtech Strategy On US Successes

The UK medtech industry sees the US very much as both a vital market and learning ground for future business and health-care system successes. That was the tone at recent meetings involving the UK industry association, which is ramping up its US-facing activity.

UK Accelerated Access Review Can Create A Post-Brexit 'Medtech Powerhouse'

Medical technology stakeholders in the UK will be poring over the detail of the much-anticipated Accelerated Access Review (AAR), the final report of which was released Oct. 24. The initial response from the industry has been positive.

UK Diagnostic Fret Over Loss of Support In Evidence Centers Restructure

Changes are afoot for the four UK Diagnostic Evidence Co-operatives that help generate clinical and cost-effectiveness data for innovative IVDs. Companies worry it could mean diagnostic industry needs get lost among broad medtech targets. Also, a roundup of the British In Vitro Diagnostics Association's key priorities, including the EU IVD Regulation, procurement issues, antimicrobial resistance, and of course, Brexit, highlighted at the group's 2016 annual meeting.

Related Content

Topics

UsernamePublicRestriction

Register

MT103934

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel